Kava and Kava hepatotoxicity: Requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence

Phytotherapy Research

Volumn 25, Issue 9, 2011, Pages 1263-1274

  Teschke, Rolf ^a   Qiu, Samuel X ^b   Xuan, Tran Dang ^c   Lebot, Vincent ^d  

^a GOETHE UNIVERSITY   (Germany)

^b SOUTH CHINA INSTITUTE OF BOTANY   (China)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d CIRAD   (France)

Author keywords

anxiety disorders; drug induced liver injury; herbal hepatotoxicity; kava; kava hepatotoxicity; Piper methysticum

Indexed keywords

AFLATOXIN B1; AFLATOXIN B2; AFLATOXIN G1; AFLATOXIN G2; CYTOCHROME P450; FLAVOKAVAIN B; HERBACEOUS AGENT; HYDROLASE; KAVA EXTRACT; KAVALACTONE; KAVALACTONE HYDROLASE; NON PRESCRIPTION DRUG; OCHRATOXIN; PLACEBO; UNCLASSIFIED DRUG; AFLATOXIN; KAVA; PLANT EXTRACT;

AFLATOXICOSIS; ANALYTIC METHOD; ANXIETY DISORDER; BEVERAGE; CLINICAL RESEARCH; CYTOTOXICITY; DIET SUPPLEMENTATION; DRUG CONTAMINATION; DRUG IMPURITY; DRUG ISOLATION; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; ETHNOBOTANY; EVIDENCE BASED MEDICINE; FOOD COMPOSITION; FOOD QUALITY; HUMAN; LIVER PROTECTION; LIVER TOXICITY; NONHUMAN; PHOTOCHEMISTRY; PIPER METHYSTICUM; PLANT LEAF; PLANT ROOT; PLANT STEM; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; RHIZOME; TOXIN ANALYSIS; TRADITIONAL MEDICINE; TRANQUILIZING ACTIVITY; ANIMAL; CHEMISTRY; PACIFIC ISLANDS; TOXIC HEPATITIS; TOXICITY; TOXICITY TESTING;

ASPERGILLUS; FUNGI; PIPER METHYSTICUM;

AFLATOXINS; ANIMALS; BEVERAGES; DRUG-INDUCED LIVER INJURY; ETHNOBOTANY; HUMANS; KAVA; PACIFIC ISLANDS; PLANT EXTRACTS; TOXICITY TESTS;

EID: 80052301875     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3464     Document Type: Review

References (94)

1. Anfossi L, Calderara M, Baggiani C, Giovannoli C, Arletti E, Giraudi G,. 2008. Development and application of solvent-free extraction for the detection of aflatoxin M1 in dairy products by enzyme immunoassay. J Agric Food Chem 56: 1852-1857. (Pubitemid 351497838)
2. Anke J, Ramzan I,. 2004a. Kava hepatotoxicity: Are we any closer to the truth? Planta Med 70: 193-196. (Pubitemid 38445182)
3. Anke J, Ramzan I,. 2004b. Pharmacokinetic and pharmacodynamic drug interactions with kava (Piper methysticum Forst. f.). J Ethnopharmacol 93: 153-160. (Pubitemid 38962400)
4. Azziz-Baumgartner E, Lindblade K, Gieseker K, et al,. 2005. Case-control study of an acute aflatoxicosis outbreak, Kenya, 2004. Environ Health Perspect 113: 1779-1783. (Pubitemid 41794276)
5. Codex Alimentarius. Commission E. Discussion Paper on the Development of a Standard for Kava. Joint FAO/WHO Food Standards Programme, September 2010, eleventh session, CX/NASWP 10/11/8. Available at: [Accessed November 7, 2010 ]
6. Denham A, McIntyre M, Whitehouse J,. 2002. Kava-the unfolding story: report on a work-in-progress. J Altern Complement Med 8: 237-263. (Pubitemid 34753400)
7. Devanesen D, Furber M, Hampton D,. 1986. Health Indicators in the Northern Territory. Northern Territory Department of Health: Darwin.
8. DiSilvestro RA, Zhang W, DiSilvestro DJ,. 2007. Kava feeding in rats does not cause liver injury nor enhance galactosamine-induced hepatitis. Food Chem Toxicol 45: 1293-1300. (Pubitemid 46590569)
9. Dragull K, Yoshida WY, Tang CS,. 2003. Piperidine alkaloids from Piper methysticum. Phytochemistry 63: 193-198. (Pubitemid 36560138)
10. Duffield AM, Jamieson DD, Lidgard RO, Duffield PH, Bourne DJ,. 1989. Identification of some human urinary metabolites of the intoxicating beverage kava. J Chromatogr 475: 273-281. (Pubitemid 19193596)
11. FDA. 2002. (U.S. Food and Drug Administration): Consumer advisory: Kava-containing dietary supplements may be associated with severe liver injury. Issued March 25, 2002. Available at: [Accessed November 7, 2010]
12. Ferrer Amate C, Unterluggauer H, Fischer RJ, Fernández-Alba AR, Masselter S,. 2010. Development and validation of a LC-MS/MS method for the simultaneous determination of aflatoxins, dyes and pesticides in spices. Anal Bioanal Chem 397: 93-107.
13. Food Standards Australia New Zealand. 2005. Kava. A human health risk assessment. Technical report Series No.30. 2005. Available at: [Accessed November 7, 2010]
14. Garon D, El Kaddoumi A, Carayon A, Amiel C,. 2010. FT-IR spectroscopy for rapid differentiation of Aspergillus flavus, Aspergillus fumigatus, Aspergillus parasiticus and characterization of aflatoxigenic isolates collected from agricultural environments. Mycopathologica 170: 131-142.
15. Guo L, Shi Q, Dial S, et al,. 2010. Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies changes in drug metabolizing genes and potential mechanisms linked to kava hepatotoxicity. Food Chem Toxicol 48: 686-689.
16. Hänsel R,. 1968. Characterization and physiological activity of some kava constituents. Pacific Sci 22: 369-373.
17. Huang B, Han Z, Cai Z, Wu Y, Ren Y,. 2010. Simultaneous determination of aflatoxins B1, B2, G1, G2, M1 and M2 in peanuts and their derivative products by ultra-high-performance liquid chromatography-tandem mass spectrometry. Anal Chim Acta 662: 62-68.
18. Jhoo JW, Freeman JP, Heinze TM, et al,. 2006. In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum). J Agric Food Chem 54: 3157-3162.
19. Johnson BM, Qiu SX, Zhang S, et al,. 2003. Identification of novel electrophilic metabolites of Piper methysticum Forst (kava). Chem Res Toxicol 16: 733-740. (Pubitemid 36736604)
20. Krishnamachari KA, Bhat RV, Nagarajan V, Tilak TB,. 1975. Hepatitis due to aflatoxicosis. An outbreak in Western India. Lancet 7915: 1061-1063.
21. Lasme P, Davrieux F, Montet D, Lebot V,. 2008. Quantification of kavalactones and determination of kava (Piper methysticum) chemotypes using near-infrared reflectance spectroscopy for quality control in Vanuatu. J Agric Food Chem 56: 4976-4981. (Pubitemid 352039092)
22. Lebot V,. 1997. An overview of kava production in the Pacific Islands: what we do know and what we don't know. J South Pacific Agric Univ South Pacific 4: 55-62.
23. Lebot V,. 2006. The quality of kava consumed in the South Pacific. HerbalGram 71: 34-37.
24. Lebot V, Arhadya M, Manshardt R,. 1991. Geographical survey of genetic variation in kava (Piper methysticum). Pacific Sci 45: 169-185.
25. Lebot V, Johnston E, Zheng QY, McKern D, McKenna D,. 1999. Morphological, phytochemical and genetic variation in Hawaiian cultivars of 'Awa (Kava, Piper methysticum, Piperaceae). Econ Bot 53: 407-418. (Pubitemid 30018125)
26. Lebot V, Lévesque J,. 1989. The origin and distribution of kava (Piper methysticum Forst. F. Piperaceae): A phytochemical approach. Allertonia 5: 223-281.
27. Lebot V, Lévesque J,. 1996. Genetic control of kavalactone chemotypes in Piper methysticum cultivars. Phytochemistry 43: 397-403. (Pubitemid 27065556)
28. Lebot V, Merlin M, Lindstrom L,. 1997. Kava, the Pacific Elixir. Yale University Press: New Haven.
29. Lechtenberg M, Quandt B, Schmidt M, Nahrstedt A,. 2008. Is the alkaloid pipermethystine connected with the claimed liver toxicity of kava products? Pharmazie 63: 71-74. (Pubitemid 351187597)
30. Li XZ, Ramzan I,. 2010. Role of ethanol in kava hepatotoxicity. Phytother Res 24: 475-480.
31. Lieber CS,. 1997. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 77: 517-544. (Pubitemid 27184347)
32. Lim ST, Dragull K, Tang CS, Bittenbender HC, Efird JT,. 2007. Effect of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci 97: 214-221. (Pubitemid 47072170)
33. Loew D, Franz G,. 2003. Quality aspects of traditional and industrial kava-extracts. Phytomedicine 10: 610-612. (Pubitemid 37092690)
34. Lõpez Grío SJ, Garrido Frenich A, Martínez Vidal JL, Romero-González R,. 2010. Determination of aflatoxins B1, B2, G1, G2 and ochratoxin A in animal feed by ultra high-performance liquid chromatography-tandem mass spectrometry. J Sep Sci 33: 502-508.
35. Lüde S, Török M, Dieterle S, Jäggi R, Büter KB, Krähenbühl S,. 2008. Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine 15: 120-131. (Pubitemid 350297905)
36. Lupo A, Roebuck C, Dutcher M, Kennedy J, Abouzied M,. 2010. Validation study of a rapid ELISA for detection of aflatoxin in corn. Performance Tested Method 050901. AOAC Int 93: 587-599.
37. Mandavilli A,. 2003. Natural-born killers. Nat Med 9: 634-635. (Pubitemid 36749202)
38. Mathews JD, Riley MD, Fejo L, et al,. 1988. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an Aboriginal community. Med J Aust 148: 548-555.
39. Ngindu A, Johnson BK, Ngira JA, et al,. 1982. Outbreak of acute hepatitis caused by aflatoxin poisoning in Kenya. Lancet 319: 1346-1348. (Pubitemid 12119225)
40. Quinto M, Spadaccino G, Palermo C, Centonze D,. 2009. Determination of aflatoxins in cereal flours by solid-phase microextraction coupled with liquid chromatography and post-column photochemical derivatization-fluorescence detection. J Chromatogr A 1216: 8636-8641.
41. Official Journal of the European Union. 2004. Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use. 2004 L 136/85.
42. Pittler MH, Ernst E,. 2003. Kava extract for treating anxiety (Cochrane Review). In Cochrane Library, Issue I, Oxford: Update Software.
43. Reagan-Shaw S, Nihal M, Ahmad N,. 2008. Dose translation from animal to human studies revisited. FASEB J 22: 659-661. (Pubitemid 351348146)
44. Russmann S, Barguil Y, Cabalion P, Kritsanida M, Duhet D, Lauterburg BH,. 2003. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol 15: 1033-1036. (Pubitemid 37094305)
45. Sarris J, Adams J, Kavanagh D,. 2010. An explorative qualitative analysis of participants' experience of using kava versus placebo in an RCT. Aust J Med Herbalism 22: 12-16.
46. Sarris J, Adams J, Wardle JL,. 2009a. Time for a reassessment of the use of kava in anxiety? Complement Ther Med 17: 121-122.
47. Sarris J, Kavanagh DJ,. 2009. Kava and St. John's wort: Current evidence for use in mood and anxiety disorders. J Altern Complement Med 15: 827-836.
48. Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G,. 2009b. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology 205: 399-407.
49. Sarris J, LaPorte E, Schweitzer I,. 2011a. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry 45: 27-35.
50. Sarris J, Teschke R, Stough C, Scholey A, Schweitzer I,. 2011b. Re-introduction of kava (Piper methysticum) to the EU: Is there a way forward? Planta Med 77: 107-110. DOI: http://dx.doi.org/ 10.1055/s-0030-1250290.
51. Schmidt M,. 2003. Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory. Letter to the Editor. J Altern Complement Med 9: 183-188. (Pubitemid 36506114)
52. Schmidt M,. 2007. Quality criteria for kava. HerbalGram 73: 45-49.
53. Schmidt M, Morgan M, Bone K, McMillan J,. 2005. Kava: a risk-benefit assessment. In The Essential Guide to Herbal Safety, Mills M, Bone K, (eds). Elsevier Churchill Livingstone: St Louis, MI, 155-221.
54. Schulze J, Raasch W, Siegers CP,. 2003. Toxicity of kava pyrones, drug safety and precautions- a case study. Phytomedicine 10 (Suppl IV): 68-73. (Pubitemid 36597161)
55. Semagn K, Bjørnstad Å, Marøy AG, Tarkegne Y, Manilal W,. 2006. Distribution of DArT, AFLP and SSR markers in a genetic linkage map of a doubled-haploid hexaploid wheat population. Genome 49: 545-555. (Pubitemid 44284778)
56. Siméoni P, Lebot V,. 2002. Identification of factors determining kavalactone content in Kava (Piper methysticum Forst. F.). Biochem System Ecol 30: 413-424. (Pubitemid 34555944)
57. Smith RM,. 1983. Kava lactones in Piper methysticum from Fiji. Phytochemistry 22: 1055-1056.
58. SPC Report. 2001. Pacific Kava: A Producer's Guide. Secretariat of the Pacific Community: Suva, Fiji Islands. ISBN 982-203-810-0
59. Strahl S, Ehret V, Dahm HH, Maier KP,. 1998. Necrotising hepatitis after taking herbal remedies. Dtsch Med Wschr 123: 1410-1414. (Article in German) (Pubitemid 28545594)
60. Stroka J, Petz M, Joerissen U, Anklam E,. 1999. Investigation of various extractants for the analysis of aflatoxin B1 in different food and feed matrices. Food Add Contam 16: 331-338. (Pubitemid 29368880)
61. Tandon HD, Tandon BN, Ramalingaswami V,. 1978. Epidemic of toxic hepatitis in India of possible mycotoxic origin. Arch Pathol Lab Med 102: 372-376. (Pubitemid 8379835)
62. Tang J, Dunlop RA, Rowe A, Rodgers KJ, Ramzan I,. 2011. Kavalactones yangonin and methysticin induce apoptosis in human hepatocytes (HepG2) in vitro. Phytother Res 25: 417-423.
63. Teschke R,. 2010a. Kava hepatotoxicity-a clinical review. Ann Hepatol 9: 251-265.
64. Teschke R,. 2010b. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 30: 1270-1279.
65. Teschke R, Fuchs J, Bahre R, Genthner A, Wolff A,. 2010. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. J Clin Pharm Ther 35: 545-563.
66. Teschke R, Gaus W, Loew D,. 2003. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 10: 440-446. (Pubitemid 36745169)
67. Teschke R, Gellert J,. 1986. Hepatic microsomal ethanol-oxidizing system (MEOS): Metabolic aspects and clinical implications. Alcoholism Clin Exp Res 10 (Suppl): 20-32. (Pubitemid 17232280)
68. Teschke R, Genthner A, Wolff A,. 2009. Kava hepatotoxicity: Comparison of aqueous, ethanolic, acetonic kava extracts and kava-herb mixtures. J Ethnopharmacol 123: 378-384.
69. Teschke R, Hasumura Y, Joly JG, Ishii H, Lieber CS,. 1972. Microsomal ethanol-oxidizing system (MEOS): Purification and properties of a rat liver system free of catalase and alcohol dehydrogenase. Biochem Biophys Res Commun 49: 1187-1193.
70. Teschke R, Hasumura Y, Lieber CS,. 1975. Hepatic microsomal alcohol-oxidizing system: Affinity for methanol, ethanol, propanol and butanol. J Biol Chem 250: 7397-7404.
71. Teschke R, Qiu SX, Lebot V,. 2011a. Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig Liv Dis in press.
72. Teschke R, Sarris J, Glass X, Schulze J,. 2011b. Kava, the anxiolytic herb: back to basics to prevent liver injury? Br J Clin Pharmacol 71: 445-448.
73. Teschke R, Sarris J, Lebot V,. 2011c. Kava hepatotoxicity solution: A six-point plan for new kava standardization. Phytomedicine 18: 96-103.
74. Teschke R, Schulze J,. 2010. Risk of kava hepatotoxicity and the FDA consumer advisory. J Am Med Assoc 304: 2174-2175.
75. Teschke R, Schwarzenboeck A, Akinci A,. 2008a. Kava hepatotoxicity: a European view. N Zeal Med J 121: 1283 Available at: [Accessed October 16, 2010]
76. Teschke R, Schwarzenboeck A, Hennermann KH,. 2008b. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 20: 1182-1193.
77. Teschke R, Schwarzenboeck A, Hennermann KH,. 2008c. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 66: 758-766.
78. Teschke R, Wolff A,. 2009. Kava hepatotoxicity: Regulatory data selection and causality assessment. Dig Liv Dis 41: 891-901.
79. Teschke R, Wolff A,. 2011. Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate? Reg Tox Pharmacol 59: 1-7.
80. TGA. 2010. Australian Government, Department of Health and Aging, Therapeutic Goods Administration, Kava fact sheet, April 2005. Web page last updated September 20, 2010. Available at: [Accessed October 16, 2010]
81. Trucksess MW, Stoloff L,. 1981. High performance liquid chromatographic determination of aflatoxicol in milk, blood, and liver. J Assoc Off Anal Chem 64: 1083-1087.
82. Uchigashima M, Saigusa M, Yamashita H, et al,. 2009. Development of a novel immunoaffinity column for aflatoxin analysis using organic solvent-tolerant monoclonal antibody. J Agric Food Chem 57: 8728-8734.
83. Vanuatu Legislation: Kava Act 2002. Available at: [Accessed October 16, 2010]
84. Weaver CM, Trucksess MW,. 2010. Determination of aflatoxins in botanical roots by a modification of AOAC Official Method 991.31: single-laboratory validation. J AOAC Int 93: 184-189.
85. Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS,. 2003. Kava lactones and kava-kava controversy. Phytochemistry 64: 673-679.
86. WHO (World Health Organization). 2007. Assessments of the Risk of Hepatotoxicity with Kava Products. WHO Document Production Services: Geneva, Switzerland.
87. Wild CP, Gong YY,. 2010. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 31: 71-82.
88. Xuan TD, Fukuta AA, Ao CW, Elzaawely AA, Khanh TD, Tawata S,. 2008. Efficacy of extracting solvents to chemical compounds of kava (Piper methysticum) root. J Nat Med 62: 188-194. (Pubitemid 351365814)
89. Yamazaki Y, Hashida H, Arita A, Hamaguchi K, Shimura F,. 2008. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem Toxicol 46: 3732-3738.
90. Yueh MF, Kawahara M, Raucy J,. 2005. High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos 33: 38-48. (Pubitemid 40023512)
91. Zhang LY, Rowe A, Ramzan I,. 2010. Does inflammation play a role in kava hepatotoxicity? Phytother Res 25: 629-630.
92. Zhou P, Gross S, Liu JH, et al,. 2010. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-κB and MAPK signalling pathways. FASEB J 24: 4722-4732.
93. Zou L, Harkey MR, Henderson GL,. 2002. Effects of herbal components on coda-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71: 1579-1589. (Pubitemid 34808718)
94. Zou L, Harkey MR, Henderson GL, Dike LE,. 2004. Kava does not display metabolic toxicity in a homogeneous cellular assay. Planta Med 70: 289-292. (Pubitemid 38594597)